TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $43.80.

Several brokerages have recently weighed in on TMDX. Zacks Investment Research downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research note on Tuesday. Cowen lowered their target price on TransMedics Group from $49.00 to $39.00 and set an “outperform” rating for the company in a research note on Friday, October 8th. Morgan Stanley lowered their target price on TransMedics Group from $33.00 to $22.00 and set an “equal weight” rating for the company in a research note on Friday, January 7th. Finally, JPMorgan Chase & Co. raised their target price on TransMedics Group from $29.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday, October 14th.

NASDAQ:TMDX opened at $16.51 on Friday. The business’s 50-day moving average is $22.11 and its two-hundred day moving average is $27.44. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.89 and a quick ratio of 6.95. TransMedics Group has a 12 month low of $15.88 and a 12 month high of $49.50. The firm has a market capitalization of $458.45 million, a PE ratio of -11.96 and a beta of 1.71.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, November 9th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.15). The company had revenue of $5.37 million during the quarter, compared to analysts’ expectations of $7.73 million. TransMedics Group had a negative net margin of 134.15% and a negative return on equity of 41.03%. During the same period last year, the business earned ($0.19) earnings per share. Equities analysts anticipate that TransMedics Group will post -1.57 EPS for the current year.

In other news, Director Edwin M. Kania, Jr. purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 29th. The stock was acquired at an average cost of $22.56 per share, for a total transaction of $2,256,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP John F. Carey sold 1,680 shares of the firm’s stock in a transaction dated Monday, November 1st. The stock was sold at an average price of $28.16, for a total transaction of $47,308.80. The disclosure for this sale can be found here. 10.30% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Baillie Gifford & Co. lifted its holdings in TransMedics Group by 205.5% in the third quarter. Baillie Gifford & Co. now owns 1,222 shares of the company’s stock worth $40,000 after acquiring an additional 822 shares during the last quarter. Harbor Investment Advisory LLC lifted its holdings in TransMedics Group by 30.7% in the third quarter. Harbor Investment Advisory LLC now owns 1,532 shares of the company’s stock worth $51,000 after acquiring an additional 360 shares during the last quarter. UBS Group AG lifted its holdings in TransMedics Group by 28.7% in the third quarter. UBS Group AG now owns 3,025 shares of the company’s stock worth $100,000 after acquiring an additional 675 shares during the last quarter. Citigroup Inc. lifted its holdings in TransMedics Group by 79.8% in the third quarter. Citigroup Inc. now owns 3,342 shares of the company’s stock worth $111,000 after acquiring an additional 1,483 shares during the last quarter. Finally, Advisory Services Network LLC bought a new position in TransMedics Group in the second quarter worth about $118,000. 69.23% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Featured Story: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.